{"pmid":32470890,"title":"Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.","text":["Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.","J Clin Virol","Hassoun, Ali","Thottacherry, Elizabeth Dilip","Muklewicz, Justin","Aziz, Qurrat-Ul-Ain","Edwards, Jonathan","32470890"],"journal":"J Clin Virol","authors":["Hassoun, Ali","Thottacherry, Elizabeth Dilip","Muklewicz, Justin","Aziz, Qurrat-Ul-Ain","Edwards, Jonathan"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470890","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jcv.2020.104443","topics":["Treatment"],"weight":1,"_version_":1668167109878743040,"score":9.490897,"similar":[{"pmid":32425661,"pmcid":"PMC7229471","title":"Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.","text":["Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.","J Clin Virol","Hassoun, Ali","Thottacherry, Elizabeth Dilip","Muklewicz, Justin","Aziz, Quarrat-Ul-Ain","Edwards, Jonathan","32425661"],"journal":"J Clin Virol","authors":["Hassoun, Ali","Thottacherry, Elizabeth Dilip","Muklewicz, Justin","Aziz, Quarrat-Ul-Ain","Edwards, Jonathan"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425661","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jcv.2020.104443","e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1667352728889720833,"score":88.58026},{"pmid":32399455,"pmcid":"PMC7213824","title":"Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome.","text":["Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome.","Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS. LEARNING POINTS: Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly in younger patients.Immunosuppressive therapy may provide important additional therapeutic benefit in these patients.Tocilizumab, a specific IL-6 inhibitor, led to dramatic clinical improvement in a young patient with severe COVID-19-associated cytokine release syndrome.","Eur J Case Rep Intern Med","van Kraaij, Tom DA","Mostard, Remy Lm","Ramiro, Sofia","Magro Checa, Cesar","van Dongen, Christel Mp","van Haren, Eric Hj","Buijs, Jacqueline","Landewe, Robert Bm","32399455"],"abstract":["Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS. LEARNING POINTS: Cytokine release syndrome may cause sudden and potentially life-threatening clinical deterioration in COVID-19 pneumonia, particularly in younger patients.Immunosuppressive therapy may provide important additional therapeutic benefit in these patients.Tocilizumab, a specific IL-6 inhibitor, led to dramatic clinical improvement in a young patient with severe COVID-19-associated cytokine release syndrome."],"journal":"Eur J Case Rep Intern Med","authors":["van Kraaij, Tom DA","Mostard, Remy Lm","Ramiro, Sofia","Magro Checa, Cesar","van Dongen, Christel Mp","van Haren, Eric Hj","Buijs, Jacqueline","Landewe, Robert Bm"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399455","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.12890/2020_001675","keywords":["covid-19","cytokine release syndrome","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666714494723686400,"score":57.93222},{"pmid":32343968,"pmcid":"PMC7195070","title":"Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.","text":["Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.","Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China. Since then, COVID-19 has become a pandemic affecting more than 1.5 million people worldwide. Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH). Anti-cytokine therapy such as tocilizumab, an IL-6 receptor antagonist, is a potential treatment for COVID-19; however, data regarding the efficacy of this anti-IL-6 therapy are currently lacking. We report two cases of patients who received a diagnosis of COVID-19 complicated by CRS and were treated with tocilizumab. Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS. These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process.","Chest","Radbel, Jared","Narayanan, Navaneeth","Bhatt, Pinki J","32343968"],"abstract":["Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China. Since then, COVID-19 has become a pandemic affecting more than 1.5 million people worldwide. Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH). Anti-cytokine therapy such as tocilizumab, an IL-6 receptor antagonist, is a potential treatment for COVID-19; however, data regarding the efficacy of this anti-IL-6 therapy are currently lacking. We report two cases of patients who received a diagnosis of COVID-19 complicated by CRS and were treated with tocilizumab. Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS. These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process."],"journal":"Chest","authors":["Radbel, Jared","Narayanan, Navaneeth","Bhatt, Pinki J"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343968","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.chest.2020.04.024","keywords":["covid-19","critical care","cytokines","viral disease"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138495811321859,"score":55.227066},{"pmid":32303591,"title":"Cytokine release syndrome in severe COVID-19.","text":["Cytokine release syndrome in severe COVID-19.","Science","Moore, John B","June, Carl H","32303591"],"journal":"Science","authors":["Moore, John B","June, Carl H"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303591","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1126/science.abb8925","topics":["Treatment"],"weight":1,"_version_":1666138491107409920,"score":54.922966},{"pmid":32234467,"pmcid":"PMC7118634","title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","text":["The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19.","Int J Antimicrob Agents","Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang","32234467"],"abstract":["Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19."],"journal":"Int J Antimicrob Agents","authors":["Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234467","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105954","keywords":["covid-19","cytokine release syndrome","tocilizumab"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490384941057,"score":50.339653}]}